Enzolytics Inc (ENZC)

[falon]

It doesn't cure HIV./AIDS

It lessens the threat of HIV expanding,

It keeps it in check to some extent.

It helps strengthens the immune system.

About ITV-1 - ImmunH
Most importantly, we have successfully completed Phase III for ITV-1 – ImmunH, which is comprised of a clinical trial (see Final Report https://www.immunh.com/finalreporten) conducted in Specialized Hospital for Active Treatment of Infectious and Parasitic Deceases “Professor Ivan Kirov”, Sofia on 31 patients suffering from AIDS in the advanced stages of the disease. The results of the clinical trial can be summarized as follows:

improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8,

decrease in the viral load,

a good treatment effect on opportunistic infections,

very good compatibility with all of the other modern antiretroviral drugs,

very good tolerance in all patients and complete absence of side effects

We are currently working on completing the final Phase IV and receiving a Permit for Mass Use on the territory of Bulgaria and complete the registration process of ITV-1 – ImmunH and bring the medicine to the market. After we have registered the medicine in Bulgaria, we will be able to register ITV-1 - ImmunH in different countries across the globe with a shortened registering process due to the Mutual Recognition Agreement (MRA) for medicinal products,

OTHER DISEASES
We have tested ITV-1 – ImmunH on volunteers suffering from other diseases such as Cancer, Chronic Hepatitis B and C, Diabetes A and B, Rheumatoid Arthritis, and other severe illnesses with tremendous healing results, as the medicine stimulates the immune answer and strengthens the immune system of the human being.
https://www.immunh.com/itv-1en

Inactivated Pepsin Fragment (IPF) Technology
One Company technology, invented by Harry Zhabilov, the CSO of the Company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. HIV patients tested in these trials showed the following beneficial outcomes:

Improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8.
Decrease in the viral load.
Demonstrated beneficial effect on opportunistic infections.
Demonstrated very good compatibility with all of the other modern antiretroviral drugs.
Demonstrated very good tolerance in all patients and complete absence of side effects.
This Enzolytics anti-HIV treatment is now being advanced through the certification stage, after which it will be available for patient therapy. ITV-1 has also demonstrated a positive effect on different kinds of cancer due to its ability to stimulate the immune system.
https://enzolytics.com/proprietary-therapeutics/